Very interesting clinical question in patients with atrial fibrillation: should our choice of rate control agent influence bleeding risk in patients receiving DOAC therapy? Emerging data suggest that in patients with atrial fibrillation treated with direct oral anticoagulants such as apixaban or rivaroxaban, concomitant use of diltiazem may be associated with a higher risk of serious bleeding complications compared with metoprolol.